, Jan. 16, 2020
/PRNewswire-PRWeb/ -- NanoFUSE Biologics is pleased to announce the addition of Dr. Answorth Allen
to its Scientific Advisory Board. NanoFUSE Biologics offers a biologically enhanced synthetic therapeutic, which is the only FDA-cleared bioactive glass and demineralized bone matrix (DBM) combined medical device.
President of NanoFUSE Biologics, Jake Lubinski
, said, "As we assemble the NanoFUSE Scientific Advisory Board, we are looking for the top physicians in every discipline of orthopedics. Dr. Allen is recognized as one of the top Sports Medicine surgeons and brings extensive experience with not just biologics, but with how those biologics are used to best care for patients. We are excited to welcome Dr. Allen as the latest member to our team and our designated leading Board expert for Sports Medicine."
Dr Allen noted, "I am honored to be part of the Scientific Advisory Board for NanoFUSE. As sports medicine and orthopedic surgery continues to evolve into less invasive surgery it will be critical for surgeons to have biologic materials such as NanoFUSE that help us achieve fusion faster with consistently successful results"
Dr. Answorth Allen
is an attending orthopedic surgeon at Hospital for Special Surgery, specializing in shoulder, knee, and elbow surgery, and an associate professor of clinical orthopedic surgery at Weill Cornell Medical College in New York City
Dr. Allen received his MD degree from Weill Cornell Medical College. He completed his orthopedic residency at the New York Orthopedic Hospital and Columbia Presbyterian Medical Center, and a spine surgery fellowship at University of Pittsburgh
. He is a team orthopedist for the New York Knicks basketball team and a former team physician for the New York Mets. He is also a Team Physician for USA
Basketball. In addition, Dr. Allen is an orthopedic consultant for the West Indies Cricket Board of Control. He is the former team physician for the Long Island Rough Riders soccer team.
About NanoFUSE Biologics
NanoFUSE is a biologically enhanced synthetic therapeutic that combines osteoinductive DBM with the osteostimulative properties of bioactive glass. NanoFUSE is the only FDA-cleared combination of DBM and bioactive glass and is indicated for use in general orthopedic applications. NanoFUSE Biologics is a KICVentures portfolio company and is distributed by SpineFrontier.
KICVentures is a private investment holding company founded by Harvard
-trained Orthopedic Surgeon & Professor Dr. Kingsley R. Chin
, who brings unique experience at the intersection of medicine, business and information technology. KICVentures is equipped with a strong advantage in identifying niche healthcare opportunities and has a proven track-record of building the most disruptive spine technology portfolio, including AxioMed, NanoFUSE and SpineFrontier. It has headquarters in Boston, MA.
SOURCE NanoFUSE Biologics